Drug Landscape ›
NTG patch ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Constipation — 2 reports (16.67%) Faeces Discoloured — 2 reports (16.67%) Abdominal Pain — 1 report (8.33%) Abdominal Pain Upper — 1 report (8.33%) Anaemia — 1 report (8.33%) Asthenia — 1 report (8.33%) Blindness — 1 report (8.33%) Blood Pressure Orthostatic Abnormal — 1 report (8.33%) Cardiac Failure — 1 report (8.33%) Cerebrovascular Accident — 1 report (8.33%)
Source database →
NTG patch in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is NTG patch approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for NTG patch in United States?
Cairo University is the originator. The local marketing authorisation holder may differ — check the official source linked above.